| [1] |
Chauvin C, Salhi S, Jean-Jean O. Human eukaryotic release factor 3a depletion causes cell cycle arrest at G1 phase through inhibition of the mTOR pathway[J]. Mol Cell Biol, 2007, 27(16): 5619-5629.
|
| [2] |
Zhouravleva G, Schepachev V, Petrova A, et al. Evolution of translation termination factor eRF3: is GSPT2 generated by retrotransposition of GSPT1's mRNA?[J]. IUBMB Life, 2006, 58(4): 199-202.
|
| [3] |
Xiao R, Gao Y, Shen Q, et al. Polypeptide chain release factor eRF3 is a novel molecular partner of survivin[J]. Cell Biol Int, 2013, 37(4): 359-369.
URL
|
| [4] |
Malta-Vacas J, Ferreira P, Monteiro C, et al. Differential expression of GSPT1 GGCn alleles in cancer[J]. Cancer Genet Cytogenet, 2009, 195(2): 132-142.
|
| [5] |
Delage MM, Dutertre S, Le Guével R, et al. Monoclonal antibodies against human translation termination factor eRF3 and their utilization for sub-cellular localization of eRF3[J]. J Biochem, 2011, 150(1): 49-59.
URL
|
| [6] |
Chauvin C, Jean-Jean O. Proteasomal degradation of human release factor eRF3a regulates translation termination complex formation[J]. RNA, 2007, 14(2): 240-245.
|
| [7] |
Uchida N, Hoshino S, Imataka H, et al. A novel role of the mammalian GSPT/eRF3 associating with poly(A)-binding protein in Cap/Poly(A)-dependent translation[J]. J Biol Chem, 2002, 277(52): 50286-50292.
|
| [8] |
Jerbi S, Jolles B, Bouceba T, et al. Studies on human eRF3-PABP interaction reveal the influence of eRF3a N-terminal glycin repeat on eRF3-PABP binding affinity and the lower affinity of eRF3a 12-GGC allele involved in cancer susceptibility[J]. RNA Biol, 2016, 13(3): 306-315.
|
| [9] |
Lee JA, Park JE, Lee DH, et al. G1 to S phase transition protein 1 induces apoptosis signal-regulating kinase 1 activation by dissociating 14-3-3 from ASK1[J]. Oncogene, 2008, 27(9): 1297-1305.
|
| [10] |
Hegde R, Srinivasula SM, Datta P, et al. The polypeptide chain-releasing factor GSPT1/eRF3 is proteolytically processed into an IAP-binding protein[J]. J Biol Chem, 2003, 278(4): 38699-38706.
|
| [11] |
Le Goff C, Zemlyanko O, Moskalenko S. Mouse GSPT2, but not GSPT1, can substitute for yeast eRF3 in vivo[J]. Genes Cells, 2002, 7(10): 1043-1057.
|
| [12] |
Meric F, Hunt KK. Translation initiation in cancer: a novel target for therapy[J]. Mol Cancer Ther, 2002, 1(11): 971-997.
|
| [13] |
Basu J, Williams BC, Li Z, et al. Depletion of a Drosophila homolog of yeast Sup35p disrupts spindle assembly, chromosome segregation, and cytokinesis during male meiosis[J]. Cell Motil Cytoskeleton, 2015, 39(4): 286-302.
|
| [14] |
Jacobo-Herrera NJ, Pérez-Plasencia C, Camacho-Zavala E, et al. Clinical evidence of the relationship between aspirin and breast cancer risk (Review)[J]. Oncol Rep, 2014, 32(2): 451-461.
|
| [15] |
Wang S, Beeghly-Fadiel A, Cai Q, et al. Gene expression in triple-negative breast cancer in relation to survival[J]. Breast Cancer Res Treat, 2018, 171(1): 199-207.
|
| [16] |
Malta-Vacas J, Chauvin C, Gonçalves L,et al. eRF3a/GSPT1 12-GGC allele increases the susceptibility for breast cancer development[J]. Oncol Rep, 2009, 21(6): 1551-1558.
|
| [17] |
Miri M, Hemati S, Safari F, et al. GGCn polymorphism ofeRF3a/GSPT1gene and breast cancer susceptibility[J]. Med Oncol, 2012, 29(3): 1581-1585.
|
| [18] |
Chauvin C, Salhi S, Le Goff C, et al. Involvement of Human Release Factors eRF3a and eRF3b in Translation Termination and Regulation of the Termination Complex Formation[J]. Mol Cell Biol, 2005, 25(14): 5801-5811.
|
| [19] |
Terry MB, Gaudet MM, Gammon MD. The epidemiology of gastric cancer[J]. Semin Radiat Oncol, 2002, 12(2): 111-127.
|
| [20] |
Malta-Vacas J, Aires C, Costa P, et al. Differential expression of the eukaryotic release factor 3 (eRF3/GSPT1) according to gastric cancer histological types[J]. J Clin Pathol, 2005, 58(6): 621-625.
|
| [21] |
Malta-Vacas J, Nolasco S, Monteiro C, et al. Translation termination and protein folding pathway genes are not correlated in gastric cancer[J]. Clin Chem Lab Med, 2009, 47(4): 427-431.
|
| [22] |
Tian QG, Tian RC, Liu Y, et al. The role of miR-144/GSPT1 axis in gastric cancer[J]. Eur Rev Med Pharmacol Sci, 2018, 22(13): 4138-4145.
|
| [23] |
Brito M, Malta-Vacas J, Carmona B, et al. Polyglycine expansions in eRF3/GSPT1 are associated with gastric cancer susceptibility[J]. Carcinogenesis, 2005, 26(12): 2046-2049.
|
| [24] |
Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2): 87-108.
|
| [25] |
王雅, 赵星, 马从乾, 等. 真核肽链释放因子3a/gspt1在肝癌组织中的表达[J]. 中华实验外科杂志, 2014, 31(7): 1550-1552.
|
| [26] |
刘润田, 安聪静, 白云, 等.GSTP1基因对人肝癌细胞系HepG2增殖和侵袭能力的影响[J]. 肿瘤防治研究, 2016, 43(12): 1039-1042.
|
| [27] |
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015, 136(5): E359-E386.
|
| [28] |
Xiao R, Li C, Chai B. miRNA-144 suppresses proliferation and migration of colorectal cancer cells through GSPT1[J]. Biomed Pharmacother, 2015, 74: 138-144.
|
| [29] |
Corradetti MN, Guan KL. Upstream of the mammalian target of rapamycin: do all roads pass through mTOR?[J]. Oncogene, 2006, 25(48): 6347-6360.
|
| [30] |
Nair S, Bora-Singhal N, Perumal D, et al. Nicotine-mediated invasion and migration of non-small cell lung carcinoma cells by modulatingSTMN3andGSPT1genes in an ID1-dependent manner[J]. Mol Cancer, 2014, 13(1): 173.
|
| [31] |
Wright JL, Lange PH. Newer potential biomarkers in prostate cancer[J]. Rev Urol, 2007, 9(4): 207-213.
|
| [32] |
Yang W, Kim Y, Kim TK, et al. Integration analysis of quantitative proteomics and transcriptomics data identify potential targets of frizzled-8 protein-related antiproliferative factor in vivo[J]. BJU Int, 2013, 110(11c): E1138-E1146.
|